[
    [
        {
            "time": "",
            "original_text": "研发投入约1100万，华东医药子公司多潘立酮片通过一致性评价！",
            "features": {
                "keywords": [
                    "研发投入",
                    "华东医药",
                    "多潘立酮片",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "研发投入约1100万，华东医药子公司多潘立酮片通过一致性评价！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2020年6月投资月报：医药的牛市 是从什么时候开始的？",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资月报",
                    "牛市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2020年6月投资月报：医药的牛市 是从什么时候开始的？",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "华东医药(000963.SZ)：多潘立酮片国内前三家通过一致性评价",
            "features": {
                "keywords": [
                    "华东医药",
                    "多潘立酮片",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)：多潘立酮片国内前三家通过一致性评价",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药：多潘立酮片通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "华东医药",
                    "多潘立酮片",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：多潘立酮片通过仿制药一致性评价",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【兴证医药】CXO（创新药产业链）的过去、现在和未来----医药行业周报",
            "features": {
                "keywords": [
                    "兴证医药",
                    "CXO",
                    "创新药产业链",
                    "医药行业周报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【兴证医药】CXO（创新药产业链）的过去、现在和未来----医药行业周报",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]